BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211002
DTSTAMP:20260515T212834
CREATED:20210521T123937Z
LAST-MODIFIED:20210521T124307Z
UID:30236-1632873600-1633132799@www.pharmajournalist.com
SUMMARY:12th Annual World Bispecific Summit
DESCRIPTION:The 12th Annual World Bispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery\, translational\, and manufacturing challenges faced in the bispecific field. Whatever your role and interest\, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients. \n \nDiscover who the 45+ expert speakers are\, and the topics they will examine\, including how: \n\nOSE Immunotherapeutics is pioneering their unique platform BiCKI a bispecific platform optimized for the development and manufacturing of bispecific cytokine fusion proteins\nGT Biopharma and Light Chain Bioscience are showcasing the next generation of innate cell engagers for the treatment of solid tumors\nMerus\, Pfizer\, and Innate Pharma are expanding the boundaries of biotherapeutics with tri-specific and multi-specific antibodies\nGenentech\, Pfizer\, and City of Hope are discussing approaches to reduce on-target off-tumor toxicities including dosing strategies in liquid and solid tumor indications\nXencor\, Harbour Biomed\, and Harpoon Therapeutics will discuss their unique platforms and CMC strategies for scale-up and production\nIGM Biosciences and MacroGenics will evaluate biomarker strategies for bispecific candidates during clinical development\n\nTo know more about 12th Annual World Bispecific Summit please click here.
URL:https://www.pharmajournalist.com/event/12th-annual-world-bispecific-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR